AR063376A1 - Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento - Google Patents
Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamientoInfo
- Publication number
- AR063376A1 AR063376A1 ARP070104708A ARP070104708A AR063376A1 AR 063376 A1 AR063376 A1 AR 063376A1 AR P070104708 A ARP070104708 A AR P070104708A AR P070104708 A ARP070104708 A AR P070104708A AR 063376 A1 AR063376 A1 AR 063376A1
- Authority
- AR
- Argentina
- Prior art keywords
- metabolites
- hydroxy
- derivatives
- demetilvenlafaxine
- oxide
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 title abstract 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
- C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
- C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente proporciona compuestos aislados caracterizados como metabolitos o derivados de desmetilvenlafaxina incluyendo metabolitos de hidroxi-DV, metabolitos de hidroxi-DV-glucuronido, metabolitos de N-oxido-DV, y metabolitos de bencil-hidroxi- DV. La presente incluye composiciones farmacéuticas que comprenden cualquiera de los metabolitos o derivados de esta solicitud en combinacion con un portador o excipiente farmacéuticamente aceptable. También se incluye un método de tratamiento de al menos un trastorno del sistema nervioso central en un mamífero, que comprende suministrar a un mamífero que necesite del mismo, una cantidad efectiva de los compuestos de la presente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85406306P | 2006-10-25 | 2006-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063376A1 true AR063376A1 (es) | 2009-01-28 |
Family
ID=39103391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104708A AR063376A1 (es) | 2006-10-25 | 2007-10-24 | Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080261895A1 (es) |
| EP (1) | EP2086922A2 (es) |
| JP (1) | JP2010507667A (es) |
| CN (1) | CN101528667A (es) |
| AR (1) | AR063376A1 (es) |
| CA (1) | CA2666350A1 (es) |
| CL (1) | CL2007003067A1 (es) |
| MX (1) | MX2009004247A (es) |
| PE (1) | PE20081138A1 (es) |
| RU (1) | RU2009112105A (es) |
| TW (1) | TW200826925A (es) |
| WO (1) | WO2008051558A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7696383B2 (en) * | 2007-06-26 | 2010-04-13 | Solvay Pharmaceuticals B.V. | N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs |
| CN109761826B (zh) * | 2019-01-17 | 2022-02-25 | 烟台大学 | 一种o-去甲基文拉法辛苯醚化合物及其制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| DE69429895T2 (de) * | 1993-06-28 | 2002-08-29 | American Home Products Corp., Madison | Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten |
| AU2002250058B2 (en) * | 2001-02-12 | 2007-08-16 | Wyeth Llc | Novel succinate salt of O-desmethyl-venlafaxine |
-
2007
- 2007-10-24 AR ARP070104708A patent/AR063376A1/es unknown
- 2007-10-24 CA CA002666350A patent/CA2666350A1/en not_active Abandoned
- 2007-10-24 PE PE2007001445A patent/PE20081138A1/es not_active Application Discontinuation
- 2007-10-24 JP JP2009534631A patent/JP2010507667A/ja active Pending
- 2007-10-24 MX MX2009004247A patent/MX2009004247A/es not_active Application Discontinuation
- 2007-10-24 US US11/976,413 patent/US20080261895A1/en not_active Abandoned
- 2007-10-24 RU RU2009112105/04A patent/RU2009112105A/ru not_active Application Discontinuation
- 2007-10-24 EP EP07852918A patent/EP2086922A2/en not_active Withdrawn
- 2007-10-24 CL CL200703067A patent/CL2007003067A1/es unknown
- 2007-10-24 WO PCT/US2007/022525 patent/WO2008051558A2/en not_active Ceased
- 2007-10-24 CN CNA2007800394478A patent/CN101528667A/zh active Pending
- 2007-10-25 TW TW096140034A patent/TW200826925A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008051558A3 (en) | 2008-08-14 |
| CN101528667A (zh) | 2009-09-09 |
| PE20081138A1 (es) | 2008-09-18 |
| WO2008051558A2 (en) | 2008-05-02 |
| JP2010507667A (ja) | 2010-03-11 |
| EP2086922A2 (en) | 2009-08-12 |
| CL2007003067A1 (es) | 2008-04-11 |
| CA2666350A1 (en) | 2008-05-02 |
| TW200826925A (en) | 2008-07-01 |
| RU2009112105A (ru) | 2010-11-27 |
| US20080261895A1 (en) | 2008-10-23 |
| MX2009004247A (es) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA118645C2 (uk) | Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін | |
| CL2011000043A1 (es) | Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central. | |
| ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
| ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
| ECSP088823A (es) | Quinazolinas para la inhibición de pdk1 | |
| MX362693B (es) | Composición para el cuidado oral para tratar y/o prevenir afecciones causadas por microorganismos, usando un dispositivo oral de luz. | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| ATE482209T1 (de) | Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität | |
| ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| CY1114363T1 (el) | Ανθελμινθικος συνδυασμος | |
| CR20110103A (es) | Heteroarilos sustituidos | |
| CL2012000702A1 (es) | Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson. | |
| CL2007000311A1 (es) | Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer. | |
| CL2009001274A1 (es) | Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer. | |
| MX2010002316A (es) | Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales. | |
| EA201001412A1 (ru) | Ингибиторы киназы pim и способы их применения | |
| CL2011003350A1 (es) | Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| MX2018013333A (es) | Composiciones de nucleasas terapeuticas y metodos. | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| MY159955A (en) | Certain chemical entities, compositions and methods | |
| GT201200193A (es) | Derivados de aril triazol heteroarmoaticos como inhibidores de enzima pde10a | |
| BR112012026707A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado | |
| BRPI0908635B8 (pt) | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
| CR11290A (es) | Derivados de ciclopropilamida | |
| MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |